Shaping the future of pathology

We deliver high‑quality laboratory and diagnostic services, performing more than 65 million tests every year. With a portfolio of over 6,000 assays, our accredited labs provide everything from routine blood tests to advanced molecular and genetic analysis – giving you fast, reliable answers when they matter most.

Explore

Our NHS Partnerships

Test database

Our database hosts almost 2,000 diagnostic tests. Use our user-friendly search feature for full user details including how to order tests, collect samples, and interpret results.

View

Research & Innovation

£0m+ invested in

employee-led innovation and research projects since 2022

1st urban drone deliveries

of pathology samples in the UK

0 hospital sites

supported to roll out Rapid Pathogen Metagenomics

News & resources

SYNLAB UK&I joins the Equalex Employer Charter

Talent, not background, should determine the next generation of healthcare scientists. SYNLAB UK&I has strengthened its commitment to improving employment opportunities for young Londoners by signing the Equalex Employer Charter. This is a shared commitment between us and the Central London Careers Hub to provide high quality and inclusive work experience for young people. We [...]

Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients

NHS England became the world’s first health service to roll out circulating tumour DNA (ctDNA) testing for suspected lung cancer in 2025 Synnovis* have supported this initiative from its pilot phase and now provide ctDNA testing for over a third of eligible NHS patients in England including those from South London, Kent, Sussex, Surrey, West [...]

Synnovis supports development to dramatically reduce pre-transfusion testing times for myeloma patients

Validation work undertaken by Synnovis Biomedical Scientist, Molly Rutherford, has the potential to significantly improve the blood transfusion experience for patients receiving daratumumab, a treatment widely used for multiple myeloma. Multiple myeloma is the second most common blood cancer worldwide. Although it remains incurable, major advances in treatment have significantly improved patient outcomes, particularly following [...]